Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Leukemia, Myeloid, Acute 10Myelodysplastic Syndromes 6Leukemia, Myelomonocytic, Chronic 3Glioma 2Glioblastoma 2Cholangiocarcinoma 2Targeted Therapy 1Spinal Cord Neoplasms 1Oligodendroglioma 1Neoplasms 1Myeloproliferative Disorders 1Myeloid Malignancies 1Diffuse Intrinsic Pontine Glioma 1Carcinoma, Hepatocellular 1Brain Neoplasms 1Bile Duct Neoplasms 1Astrocytoma 1

Interventions

Temozolomide 15Radiotherapy 11Everolimus 6Bevacizumab 6Irinotecan 5Cyclophosphamide 5ribociclib 4Radiation 4Panobinostat 4TIC10 compound 3Specimen Handling 3Re-Irradiation 3Etoposide 3Dasatinib 3pembrolizumab 2nimotuzumab 2abemaciclib 2Vorinostat 2Valproic Acid 2Topotecan 2Nivolumab 2Mebendazole 2Magnetic Resonance Spectroscopy 2Granulocyte-Macrophage Colony-Stimulating Factor 2Gemcitabine 2GDC-0084 2Erlotinib Hydrochloride 2Diphtheria-Tetanus Vaccine 2Cilengitide 2Cetuximab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Diffuse Intrinsic Pontine Glioma × olutasidenib × Clear all
NCT06161974 2025-02-21

Study of Olutasidenib and Temozolomide in HGG

Rigel Pharmaceuticals

Phase 2 Recruiting
60 enrolled
CNS

Diffuse Intrinsic Pontine Glioma, Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma, Spinal Cord Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡